Welcome to the 2026 argenx Congress Hub.

Throughout 2026, argenx contributed to the scientific programmes of major international medical congresses, including AAN, PNS, EAN and ICNMD. This site brings together key argenx scientific presentations featured across these meetings.

Content is organised by indication and provides a consolidated overview of clinical trial data, real-world evidence, biomarker research and other scientific insights presented throughout the year. We hope this resource supports your review of the latest developments, foster meaningful scientific exchange, inspire future research and help drive progress that ultimately benefits patients.


Generalized Myasthenia gravis (gMG)

1 Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT

Long-Term Outcomes with Efgartigimod IV: ADAPT NXT
AAN 2026

 

2 Safety, Efficacy, and QoL Impact of Long-Term Efgartigimod PH20 SC in Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study

Long-Term Safety, Efficacy and QoL with Efgartigimod SC
EAN 2026

 

3 Real-world Impact of Efgartigimod on Treatment Burden in Heavily Pre-treated and Less Heavily Pre-treated Patients with Generalized Myasthenia Gravis in Japan

Real-World Impact of Efgartigimod on Treatment Burden
EAN 2026

 

4 Rapid, sustained improvements with efgartigimod in symptoms, daily life, and patient satisfaction in gMG: Initial results from the PREMIER study

Rapid, Sustained Improvements with Efgartigimod in the PREMIER study
AAN 2026

 

5 Trial in progress – Impact of Continuous Assessment of generalized Myasthenia Gravis using a Mobile Application: myMGverse Study

Continuous Assessment of gMG Using a Mobile Application
AAN 2026

 

6 Safety and effectiveness of efgartigimod in Japanese patients with generalized myasthenia gravis by serological profiles: analysis of post-marketing surveillance

Safety and Effectiveness of Efgartigimod across Serological Profiles
AAN 2026

 

7 Assessing Efgartigimod Dosing Patterns and Myasthenia Gravis Activities of Daily Living Outcomes in Clinical Practice: Results From a Large Patient Support Program Database in the United States

Efgartigimod Dosing Patterns and MG-ADL Outcomes in Clinical Practice
AAN 2026

 

8 Steroid tapering among patients with generalized myasthenia gravis (gMG) receiving efgartigimod: results from the STRIVE-gMG chart review

Steroid Tapering with Efgartigimod in gMG
AAN 2026

 

9 Real-World Cardiovascular Burden Among Patients with Myasthenia Gravis Across the United States, France, and Japan

Real-World Cardiovascular Burden in Myasthenia Gravis
ICNMD 2026

 

 

Chronic inflammatory demyelinating Polyradiculoneuropathy (CIDP)

10 Beyond Disability: The Burden of Fatigue in CIDP

The Burden of Fatigue in CIDP
AAN 2026

 

11 Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20

Physician Insights on Transitioning from IVIg to Efgartigimod SC
AAN 2026

 

12 Characteristics of Real-World Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Initiating Subcutaneous Efgartigimod in the United States

Characteristics of Real-World Patients Initiating Efgartigimod SC
AAN 2026

 

13 Characterization of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) initiating subcutaneous efgartigimod (SC-EFG) in the United States: Insights from a patient support program

Characterisation of CIDP Patients Initiating Efgartigimod SC
PNS 2026

 

14 Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20 Transition in CIDP: Results From a Phase 4, Open-Label, Single-Group, Multicenter Study

IVIg to Efgartigimod SC Transition in CIDP
EAN 2026

 

15 Real-World Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design

ADHERE REAL Study Design: Real-World Use of Efgartigimod
EAN 2026

 

16 Impact of Efgartigimod on Inflammatory Neuropathy Cause and Treatment Scores: ADHERE/ADHERE+ Post Hoc Analysis

Impact of Efgartigimod on INCAT Scores
PNS 2026

 

17 Neurofilament Light Chain as a Biomarker in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights From ADHERE

Neurofilament Light Chain as a Biomarker in CIDP
PNS 2026

 

18 IgG Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Interpreting Glycolipid Reactivity From the ADHERE Trial

IgG Autoantibody Signatures in CIDP
PNS 2026

 

 

Pipeline

19 Efficacy and Safety of Efgartigimod in Acetylcholine Receptor Antibody–Negative Generalized Myasthenia Gravis: Initial Results of ADAPT SERON

Efficacy and Safety of Efgartigimod in AChR-negative gMG
EAN 2026

 

20 Efficacy and Safety of Efgartigimod PH20 SC via Prefilled Syringe in Adults With oMG: ADAPT OCULUS Interim Results

Efficacy and Safety of Efgartigimod SC in ocular MG
EAN 2026

 

21 Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis: Results From the ADAPT JR Study

Efgartigimod in Juvenile gMG
ICNMD 2026

 

22 Design of Phase 2a Study Evaluating Empasiprubart Add-On Therapy to Efgartigimod in Adults With gMG

Empasiprubart Add-On Therapy to Efgartigimod in gMG
AAN 2026

 

23 Empasiprubart Versus Placebo (EMNERGIZE) or Immunoglobulin (EMVIGORATE) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Study Designs

Empasiprubart in CIDP: EMNERGIZE and EMVIGORATE
EAN 2026

 

24 Burden of Illness for Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey

Burden of Illness in Multifocal Motor Neuropathy
PNS 2026

 

25 Understanding the Patient Journey in Multifocal Motor Neuropathy (MMN): Descriptive Insights From the iMMersioN Study

Understanding the Patient Journey in MMN: iMMersion study
PNS 2026

 

26 Long-Term Safety and Efficacy Data of Empasiprubart in Multifocal Motor Neuropathy: Phase 2 ARDA+ Study

Long-Term Empasiprubart in MMN: Phase 2 ARDA+ Study
PNS 2026

 

27 Patient-Reported Outcomes and Safety From the Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Patient-Reported Outcomes with Empasiprubart in MMN
EAN 2026

 

28 Evaluation of the Effect of Empasiprubart on Nerve Morphology in Multifocal Motor Neuropathy: Study Design

Effect of Empasiprubart on Nerve Morphology in MMN
ICNMD 2026

 

29 Adimanebart (ARGX-119): A First-in-Class, Humanized, Agonistic Monoclonal Antibody With Therapeutic Potential in Neuromuscular Junction Disorders

Adimanebart in Neuromuscular Junction Disorders
ICNMD 2026

 

30 In Vivo Effects of a MuSK Agonist Antibody Against Mutation-Specific Congenital Myasthenic Syndromes

MuSK Agonist Antibody in Congenital Myasthenic Syndromes
ICNMD 2026

 

31 Phase 1b Study of Safety and Efficacy of Adimanebart (ARGX-119) in DOK7 Congenital Myasthenic Syndromes

Adimanebart in DOK7 Congenital Myasthenic Syndromes
ICNMD 2026

 

32 Efgartigimod Is a Unique FcRn Blocker That Allows IgG Reduction Without Broad Inhibition of Immune Responses

IgG Reduction with FcRn Blockade
AAN 2026

 

33 Safety of Intravenous and Subcutaneous Efgartigimod Across Multiple Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases

Safety of IV and SC Efgartigimod Across Clinical Trials
PNS 2026

 

34 Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy: Results From the Phase 2 Randomized ALKIVIA and Open-Label Extension ALKIVIA+ Trials

Efgartigimod in Idiopathic Inflammatory Myopathy
ICNMD 2026